The inflammatory syndrome: The role of adipose tissue cytokines in metabolic disorders linked to obesity

Journal of the American Society of Nephrology

Volumn 15, Issue 11, 2004, Pages 2792-2800

  Wisse, Brent E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; HORMONE;

ADIPOSE TISSUE; ATHEROSCLEROSIS; BLOOD PRESSURE; BODY MASS; DIABETES MELLITUS; DISEASE COURSE; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INFECTION; INFLAMMATION; INSULIN RESISTANCE; KIDNEY FAILURE; METABOLIC DISORDER; OBESITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; WAIST CIRCUMFERENCE; ANIMAL; METABOLIC SYNDROME X; METABOLISM; SYNDROME;

ADIPOSE TISSUE; ANIMALS; CYTOKINES; HUMANS; INFLAMMATION; METABOLIC SYNDROME X; OBESITY; SYNDROME;

EID: 16244381893     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000141966.69934.21     Document Type: Review

References (83)

1. Flegal KM, Carroll MD, Ogden CL, Johnson CL: Prevalence and trends in obesity among US adults, 1999-2000. JAMA 288: 1723-1727, 2002
2. Ogden CL, Carroll MD, Flegal KM: Epidemiologic trends in overweight and obesity. Endocrinol Metab Clin North Am 32: 741-760, vii, 2003
3. Hubert HB, Feinlab M, McNamara PM, Castelli WP: Obesity as an independent risk factor for cardiovascular disease: A 26-year follow-up of participants in the Framingham Heart Study. Circulation 67:968-977, 1983
4. Kissebah AH, Vydelingum N, Murray R, Evans DJ, Hartz AJ, Kalkhoff RK, Adams PW: Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab 54: 254-260, 1982
5. Nieves DJ, Cnop M, Retzlaff B, Walden CE, Brunzell JD, Knopp RH, Kahn SE: The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intra-abdominal fat. Diabetes 52: 172-179, 2003
6. Abate N, Garg A: Heterogeneity in adipose tissue metabolism: Causes, implications and management of regional adiposity. Prog Lipid Res.34: 53-70, 1995
7. Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37: 1595-607, 1988
8. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288: 2709-2716, 2002
9. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA 287: 356-359, 2002
10. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285: 2486-2497, 2001
11. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15: 539-553, 1998
12. Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA: Metabolic syndrome and development of diabetes mellitus: Application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol 156: 1070-1077, 2002
13. Meigs JB, D'Agostino RB Sr, Wilson PW, Cupples LA, Nathan DM, Singer DE: Risk variable clustering in the insulin resistance syndrome. The Framingham Offspring Study. Diabetes 46: 1594-1600, 1997
14. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM: Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102: 42-47, 2000
15. Pickup JC, Crook MA: Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 41: 1241-1248, 1998
16. Rader DJ: Inflammatory markers of coronary risk. N Engl J Med 343: 1179-1182, 2000
17. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM: Positional cloning of the mouse obese gene and its human homologue. Nature 372: 425-432, 1994
18. Cunningham MJ, Clifton DK, Steiner RA: Leptin's actions on the reproductive axis: perspectives and mechanisms. Biol Reprod 60: 216-222, 1999
19. Lord G: Role of leptin in immunology. Nutr Rev 60[Suppl]: S35-S8; discussion S68-S84, S85-S87, 2002
20. Rajala MW, Scherer PE: Minireview: The adipocyte - At the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 144: 3765-3773, 2003
21. Cousin B, Munoz O, Andre M, Fontanilles AM, Dani C, Cousin JL, Laharrague P, Casteilla L, Penicaud L: A role for preadipocytes as macrophage-like cells. FASEB J 13: 305-312, 1999
22. Charriere G, Cousin B, Arnaud E, Andre M, Bacou F, Penicaud L, Casteilla L: Preadipocyte conversion to macrophage. Evidence of plasticity. J Biol Chem 278: 9850-9855, 2003
23. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr: Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112: 1796-1808, 2003
24. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H: Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112: 1821-1830, 2003
25. Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG: Central nervous system control of food intake. Nature 404: 661-671, 2000
26. Legradi G, Emerson CH, Ahima RS, Flier JS, Lechan RM: Leptin prevents fasting-induced suppression of prothyrotropin-releasing hormone messenger ribonucleic acid in neurons of the hypothalamic paraventricular nucleus. Endocrinology 138: 2569-2576, 1997
27. Ahima RS, Prabakaran D, Mantzoros C, Qu D, Lowell B, Maratos-Flier E, Flier JS: Role of leptin in the neuroendocrine response to fasting. Nature 382: 250-252, 1996
28. Howard JK, Lord GM, Matarese G, Vendetti S, Ghatei MA, Ritter MA, Lechler RI, Bloom SR: Leptin protects mice from starvation-induced lymphoid atrophy and increases thymic cellularity in ob/ob mice. J Clin Invest 104: 1051-1059, 1999
29. Buttgereit F, Burmester GR, Brand MD: Bioenergetics of immune functions: Fundamental and therapeutic aspects. Immunol Today 21: 192-199, 2000
30. Tzou P, De Gregorio E, Lemaitre B: How Drosophila combats microbial infection: A model to study innate immunity and host-pathogen interactions. Curr Opin Microbiol 5(1): 102-110, 2002
31. Grunfeld C, Zhao C, Fuller J, Pollack A, Moser A, Friedman J, Feingold KR: Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters. J Clin Invest 97: 2152-2157, 1996
32. Plata-Salaman CR: Anorexia during acute and chronic disease. Nutrition 12: 69-78, 1996
33. Flier JS: Obesity wars: Molecular progress confronts an expanding epidemic. Cell 116: 337-350, 2004
34. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL, et al.: Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 334: 292-295, 1996
35. Gainsford T, Willson TA, Metcalf D, Handman E, McFarlane C, Ng A, Nicola NA, Alexander WS, Hilton DJ: Leptin can induce proliferation, differentiation, and functional activation of hemopoietic cells. Proc Natl Acad Sci U S A 93: 14564-14568, 1996
36. Raso GM, Pacilio M, Esposito E, Coppola A, Di Carlo R, Meli R: Leptin potentiates IFN-gamma-induced expression of nitric oxide synthase and cyclo-oxygenase-2 in murine macrophage J774A. 1. Br J Pharmacol 137: 799-804, 2002
37. Faggioni R, Fantuzzi G, Gabay C, Moser A, Dinarello CA, Feingold KR, Grunfeld C: Leptin deficiency enhances sensitivity to endotoxin-induced lethality. Am J Physiol 276[Suppl]: R136-R142, 1999
38. Bornstein SR, Licinio J, Tauchnitz R, Engelmann L, Negrao AB, Gold P, Chrousos GP: Plasma leptin levels are increased in survivors of acute sepsis: Associated loss of diurnal rhythm, in cortisol and leptin secretion. J Clin Endocrinol Metab 83: 280-283, 1998
39. Hasty AH, Shimano H,Osuga J, Namatame I, Takahashi A, Yahagi N, Perrey S, Iizuka Y, Tamura Y, Amemiya-Kudo M, Yoshikawa T, Okazaki H, Ohashi K, Harada K, Matsuzaka T, Sone H, Gotoda T, Nagai R, Ishibashi S, Yamada N: Severe hypercholesterolemia, hypertriglyceridemia, and atherosclerosis in mice lacking both leptin and the low density lipoprotein receptor. J Biol Chem 276: 37402-37408, 2001
40. Wallace AM, McMahon AD, Packard CJ, Kelly A, Shepherd J, Gaw A, Sattar N: Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 104: 3052-3056, 2001
41. Bataille R, Klein B: C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo. Arthritis Rheum 35: 982-984, 1992
42. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW: Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 82: 4196-4200, 1997
43. Fried SK, Bunkin DA, Greenberg AS: Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: Depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 83: 847-850, 1998
44. Bastard JP, Jardel C, Bruckert E, Blondy P, Capeau J, Laville M, Vidal H, Hainque B: Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 85: 3338-3342, 2000
45. Heinrich PC, Castell JV, Andus T: Interleukin-6 and the acute phase response. Biochem J 265: 621-636, 1990
46. Pepys MB, Hirschfield GM: C-reactive protein: A critical update. J Clin Invest 111: 1805-1812, 2003
47. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342: 836-843, 2000
48. Ridker PM, Morrow DA: C-reactive protein, inflammation, and coronary risk. Cardiol Clin 21: 315-325, 2003
49. Burke AP, Tracy RP, Kolodgie F, Malcom GT, Zieske A, Kutys R, Pestaner J, Smialek J, Virmani R: Elevated C-reactive protein values and atherosclerosis in sudden coronary death: Association with different pathologies. Circulation 105: 2019-2023, 2002
50. Burstein SA, Peng J, Friese P, Wolf RF, Harrison P, Downs T, Hamilton K, Comp P, Dale GL: Cytokine-induced alteration of platelet and hemostatic function. Stem Cells 14[Suppl 1]: 154-62, 1996
51. Wassmann S, Stumpf M, Strehlow K, Schmid A, Schieffer B, Bohm M, Nickenig G: Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor. Circ Res 94: 534-541, 2004
52. Plata-Salaman CR: Immunoregulators in the nervous system. Neurosci Biobehav Rev 15: 185-215, 1991
53. Wallenius V, Wallenius K, Ahren B, Rudling M, Carlsten H, Dickson SL, Ohlsson C, Jansson JO: Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 8: 75-79, 2002
54. Moller DE: Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab 11: 212-217, 2000
55. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM: Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 95: 2409-2415, 1995
56. Tsigos C, Kyrou I, Chala E, Tsapagos P, Stavridis JC, Raptis SA, Katsilambros N: Circulating tumor necrosis factor alpha concentrations are higher in abdominal versus peripheral obesity. Metabolism 48: 1332-1335, 1999
57. Winkler G, Kiss S, Keszthelyi L, Sapi Z, Dry I, Salamon F, Kovacs M, Vargha P, Szekeres O, Speer G, Karadi I, Sikter M, Kaszas E, Dworak O, Gero G, Cseh K: Expression of tumor necrosis factor (TNF)-alpha protein in the subcutaneous and visceral adipose tissue in correlation with adipocyte cell volume, serum TNF-alpha, soluble serum TNF-receptor-2 concentrations and C-peptide level. Eur J Endocrinol 149: 129-135, 2003
58. Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis factor-alpha: Direct role in obesity-linked insulin resistance. Science 259: 87-91, 1993
59. Cheung AT, Ree D, Kolls JK, Fuselier J, Coy DH, Bryer-Ash M: An in vivo model for elucidation of the mechanism of tumor necrosis factor-alpha (TNF-alpha)-induced insulin resistance: Evidence for differential regulation of insulin signaling by TNF-alpha. Endocrinology 139: 4928-4935, 1998
60. Lopez-Soriano J, Lopez-Soriano FJ, Bagby GJ, Williamson DH, Argiles JM: Anti-TNF treatment does not reverse the abnormalities in lipid metabolism of the obese Zucker rat. Am J Physiol 272[Suppl]: E656-E660, 1997
61. Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R: Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 45: 881-885, 1996
62. Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM: Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc Natl Acad Sci U S A 91: 4854-4858, 1994
63. Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, Karin M, Hotamisligil GS: A central role for JNK in obesity and insulin resistance. Nature 420: 333-336, 2002
64. Hotamisligil GS: Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord 27[Suppl 3]: S53-S55, 2003
65. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM: IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 271: 665-668, 1996
66. Hotamisligil GS, Budavari A, Murray D, Spiegelman BM: Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. J Clin Invest 94: 1543-1549, 1994
67. Grunfeld C, Feingold KR: The metabolic effects of tumor necrosis factor and other cytokines. Biotherapy 3: 143-158, 1991
68. Lang CH, Dobrescu C, Bagby GJ: Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology 130: 43-52, 1992
69. Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G: Adiponectin expression from human adipose tissue: Relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes 52: 1779-1785, 2003
70. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS: Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 389: 610-614, 1997
71. Ventre J, Doebber T, Wu M, MacNaul K, Stevens K, Pasparakis M, Kollias G, Moller DE: Targeted disruption of the tumor necrosis factor-alpha gene: Metabolic consequences in obese and nonobese mice. Diabetes 46: 1526-1531, 1997
72. Qiao LY, Goldberg JL, Russell JC, Sun XJ: Identification of enhanced serine kinase activity in insulin resistance. J Biol Chem 274: 10625-10632, 1999
73. Karin M, Delhase M: The I kappa B kinase (IKK) and NF-kappa B: Key elements of proinflammatory signalling. Semin Immunol 12: 85-98, 2000
74. Karin M, Ben-Neriah Y: Phosphorylation meets ubiquitination: The control of NF-κB activity. Annu Rev Immunol 18: 621-663, 2000
75. Yin MJ, Yamamoto Y, Gaynor RB: The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 396: 77-80, 1998
76. Ebstein W: Zur therapie des diabetes mellitus, insbesondere uber die anwendung der salicylsauren natron bei demselben. Berl Klin Wochenschr 24: 337-340, 1877
77. Reid J, Macdougall AI, Andrews MM: On the efficacy of salicylate in treating diabetes mellitus. BMJ 2: 1071-1074, 1957
78. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, Shoelson SE: Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkβ. Science 293: 1673-1677, 2001
79. Rohl M, Pasparakis M, Baudler S, Baumgartl J, Gautam D, Huth M, De Lorenzi R, Krone W, Rajewsky K, Bruning JC: Conditional disruption of IκB kinase 2 fails to prevent obesity-induced insulin resistance. J Clin Invest 113: 474-481, 2004
80. Jiang G, Dallas-Yang Q, Liu F, Moller DE, Zhang BB: Salicylic acid reverses phorbol 12-myristate-13-acetate (PMA)- and tumor necrosis factor alpha (TNFα)-induced insulin receptor substrate 1 (IRS1) serine 307 phosphorylation and insulin resistance in human embryonic kidney 293 (HEK293) cells. J Biol Chem 278: 180-186, 2003
81. Arita Y, Kihara S, Ouchi N, Takahaski M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257: 79-83, 1999
82. Sniderman AD, Maslowska M, Cianflone K: Of mice and men (and women) and the acylation-stimulating protein pathway. Curr Opin Lipidol 11: 291-296, 2000
83. Engeli S, Schling P, Gorzelniak K, Boschmann M, Janke J, Ailhaud G, Teboul M, Massiera F, Sharma AM: The adipose-tissue renin-angiotensin- aldosterone system: Role in the metabolic syndrome? Int J Biochem Cell Biol 35: 807-825, 2003